{"id":2970,"date":"2019-03-12T01:46:00","date_gmt":"2019-03-12T06:46:00","guid":{"rendered":"https:\/\/worldcarenew.wpenginepowered.com\/?p=2970"},"modified":"2026-03-08T02:24:28","modified_gmt":"2026-03-08T07:24:28","slug":"istrazivanje-klinike-mayo-krece-se-prema-klinickim-ispitivanjima-za-als","status":"publish","type":"post","link":"https:\/\/www.worldcare.com\/hr\/research-from-the-mayo-clinic-is-moving-towards-clinical-trials-for-als\/","title":{"rendered":"Istra\u017eivanja klinike Mayo kre\u0107u se prema klini\u010dkim ispitivanjima za ALS"},"content":{"rendered":"<p>Revolucionarno istra\u017eivanje amiotrofi\u010dne lateralne skleroze (ALS) istra\u017eiva\u010dkog tima u klinici Mayo otkrilo je 2011. godine da bi genetska ponavljaju\u0107a mutacija poznata kao c9orf72 potencijalno mogla pru\u017eiti uvid u to kako izlije\u010diti ili \u010dak sprije\u010diti ALS kod pacijenata. Ova mutacija javlja se u 40 posto svih obiteljskih slu\u010dajeva pacijenata s ALS-om i 10 posto sporadi\u010dnih slu\u010dajeva.&nbsp;<a href=\"https:\/\/www.mayo.edu\/research\/faculty\/petrucelli-leonard-ph-d\/bio-00027816?_ga=2.210979861.1604730062.1551286644-1906995952.1549485031\" target=\"_blank\" rel=\"noreferrer noopener\">Leonard Petrucelli, dr. sc.<\/a>, \u010dlan predsjedavaju\u0107eg odjela za neuroznanost na kampusu klinike Mayo na Floridi, izjavio je da je \u201cidentifikacija gena bila transformativna za to podru\u010dje, rijetko se pronalazi gen koji ima potencijal utjecati na mnogo pacijenata.\u201d Od ovog revolucionarnog otkri\u0107a, nekoliko neuroznanstvenih laboratorija na Floridi pokrenulo je studije kako bi se razdvojili u\u010dinci mutacije c9.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p>Laboratorij dr. Petrucellija otkrio je da mutacija c9 rezultira neobi\u010dnim oblikom RNA, koji omogu\u0107uje mutaciji da zaobi\u0111e signale za zdravu sintezu proteina; to rezultira nakupljanjem abnormalnih proteina. Nakon pristupa i analize banke mozga klinike Mayo koja sadr\u017ei ogromne resurse, istra\u017eiva\u010di dr. Dicksona uspjeli su prepoznati c9 kao ponavljaju\u0107u RNA, a abnormalne proteine kao jedinstvene patologije. Ove abnormalnosti su jedinstvene samo za one osobe koje imaju mutaciju c9.<\/p>\n\n\n\n<p>Daljnja istra\u017eivanja o tome kako abnormalne mutacije C9 uzrokuju ALS dovela su do otkri\u0107a jo\u0161 jednog c9 proteina nazvanog poli(GP) koji se smanjio kada su neuroni tretirani lijekovima koji ciljaju abnormalnu ponavljaju\u0107u RNA. Poli(GP) je prvi farmakodinami\u010dki marker za pacijente s ALS-om s mutacijom c9 i mogao bi pomo\u0107i u br\u017eoj dostupnosti lije\u010denja i br\u017eem isklju\u010divanju neu\u010dinkovitih, izjavio je dr. Grendon.<\/p>\n\n\n\n<p>Ovi nalazi omogu\u0107ili su razvoj klini\u010dkih ispitivanja za osobe s mutacijom. S obzirom na to da je 40 posto pacijenata s ALS-om podlo\u017eno ovoj mutaciji c9, ovaj bi proboj mogao omogu\u0107iti istra\u017eiva\u010dima da poduzmu sljede\u0107e mogu\u0107e korake u lije\u010denju ALS-a.<\/p>\n\n\n\n<p>Ako je vama ili \u010dlanu va\u0161e obitelji dijagnosticirana ALS i \u017eelite drugo medicinsko mi\u0161ljenje, molimo vas&nbsp;<a href=\"https:\/\/www.worldcare.com\/hr\/kontakt\/\">kontaktirajte nas<\/a>.<\/p>\n\n\n\n<p><strong>Izvor:<\/strong>&nbsp;<a href=\"https:\/\/advancingthescience.mayo.edu\/2019\/01\/02\/toward-clinical-trials-for-one-type-of-als\/\" target=\"_blank\" rel=\"noopener\">https:\/\/advancingthescience.mayo.edu\/2019\/01\/02\/toward-clinical-trials-for-one-type-of-als\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Groundbreaking research into amyotrophic lateral sclerosis (ALS) from a research team at Mayo Clinic discovered the genetic repeat mutation known as c9orf72 in 2011 could potentially hold insight on how to cure or possibly even prevent ALS in patients. This mutation occurs in 40 percent of all familial cases of patients with ALS and 10 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3012,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[68,69,57,70],"class_list":["post-2970","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-second-opinion","tag-als","tag-clinical-trials","tag-diagnosis","tag-medical-treatment"],"_links":{"self":[{"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/posts\/2970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/comments?post=2970"}],"version-history":[{"count":0,"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/posts\/2970\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/media\/3012"}],"wp:attachment":[{"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/media?parent=2970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/categories?post=2970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.worldcare.com\/hr\/wp-json\/wp\/v2\/tags?post=2970"}],"curies":[{"name":"radni list","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}